l1orxu

Tuberculosis surveillance and monitoring in Europe 2017
SURVEILLANCE REPORT
Table 22: Treatment outcome after 24 months of RR TB/MDR TB cases started on second-line treatment in 2013,
European Region, 2015
RR TB/MDR TB
cases started Success Died Failed Lost to follow-up b Still on treatment Not evaluated c
treatment in
2013 a N (%) N (%) N (%) N (%) N (%) N (%)
Country
on second-line
EU/EEA
Austria 16 12 (75.0) 1 (6.3) 0 (0.0) 0 (0.0) 0 (0.0) 3 (18.8)
Belgium 12 10 (83.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3) 1 (8.3)
Bulgaria 27 12 (44.4) 4 (14.8) 3 (11.1) 7 (25.9) 1 (3.7) 0 (0.0)
Croatia – – – – – – – – – – – – –
Cyprus – – – – – – – – – – – – –
Czech Republic – – – – – – – – – – – – –
Denmark 2 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0)
Estonia 50 31 (62.0) 7 (14.0) 2 (4.0) 8 (16.0) 2 (4.0) 0 (0.0)
Finland – – – – – – – – – – – – –
France – – – – – – – – – – – – –
Germany 95 39 (41.1) 7 (7.4) 3 (3.2) 9 (9.5) 9 (9.5) 28 (29.5)
Greece – – – – – – – – – – – – –
Hungary 10 3 (30.0) 2 (20.0) 0 (0.0) 1 (10.0) 1 (10.0) 3 (30.0)
Iceland – – – – – – – – – – – – –
Ireland 4 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 2 (50.0)
Italy – – – – – – – – – – – – –
Latvia 79 54 (68.4) 12 (15.2) 0 (0.0) 11 (13.9) 0 (0.0) 2 (2.5)
Liechtenstein – – – – – – – – – – – – –
Lithuania 256 76 (29.7) 59 (23.0) 13 (5.1) 71 (27.7) 35 (13.7) 2 (0.8)
Luxembourg – – – – – – – – – – – – –
Malta – – – – – – – – – – – – –
Netherlands 15 15 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Norway 6 4 (66.7) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 1 (16.7)
Poland 40 6 (15.0) 8 (20.0) 0 (0.0) 7 (17.5) 2 (5.0) 17 (42.5)
Portugal 15 8 (53.3) 0 (0.0) 0 (0.0) 2 (13.3) 4 (26.7) 1 (6.7)
Romania 573 206 (36.0) 105 (18.3) 157 (27.4) 93 (16.2) 12 (2.1) 0 (0.0)
Slovakia 2 0 (0.0) 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Slovenia 0 – – – – – – – – – – – –
Spain – – – – – – – – – – – – –
Sweden 8 6 (75.0) 1 (12.5) 0 (0.0) 0 (0.0) 1 (12.5) 0 (0.0)
United Kingdom 70 42 (60.0) 1 (1.4) 0 (0.0) 10 (14.3) 17 (24.3) 0 (0.0)
Subtotal EU/EEA 1 280 526 (41.1) 209 (16.3) 179 (14.0) 219 (17.1) 86 (6.7) 61 (4.8)
Non-EU/EEA
Albania 0 – – – – – – – – – – – –
Andorra 0 – – – – – – – – – – – –
Armenia 104 45 (43.3) 12 (11.5) 6 (5.8) 30 (28.8) – – 11 (10.6)
Azerbaijan 647 382 (59.0) 118 (18.2) 111 (17.2) 36 (5.6) – – 0 (0.0)
Belarus 2 136 1 152 (53.9) 481 (22.5) 218 (10.2) 256 (12.0) – – 29 (1.4)
Bosnia and Herzegovina 1 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) – – 0 (0.0)
former Yugoslav Republic
of Macedonia, the
2 1 (50.0) 0 (0.0) 1 (50.0) 0 (0.0) – – 0 (0.0)
Georgia 411 176 (42.8) 17 (4.1) 27 (6.6) 141 (34.3) – – 50 (12.2)
Israel 7 4 (57.1) 1 (14.3) 1 (14.3) 1 (14.3) – – 0 (0.0)
Kazakhstan 6 527 4 730 (72.5) 426 (6.5) 686 (10.5) 492 (7.5) – – 193 (3.0)
Kyrgyzstan 1 064 611 (57.4) 73 (6.9) 71 (6.7) 206 (19.4) – – 103 (9.7)
Moldova 943 538 (57.1) 93 (9.9) 112 (11.9) 194 (20.6) – – 6 (0.6)
Monaco 0 – – – – – – – – – – – –
Montenegro 0 – – – – – – – – – – – –
Russia 18 213 8 802 (48.3) 2 513 (13.8) 2 874 (15.8) 1 868 (10.3) – – 2 156 (11.8)
San Marino – – – – – – – – – – – – –
Serbia 19 15 (78.9) 0 (0.0) 1 (5.3) 3 (15.8) – – 0 (0.0)
Serbia excluding UN
Administered Province
13 10 (76.9) 0 (0.0) 0 (0.0) 3 (23.1) – – 0 (0.0)
of Kosovo d
UN Administered
Province of Kosovo d 6 5 (83.3) 0 (0.0) 1 (16.7) 0 (0.0) – – 0 (0.0)
Switzerland – – – – – – – – – – – – –
Tajikistan 625 375 (60.0) 32 (5.1) 121 (19.4) 88 (14.1) – – 9 (1.4)
Turkey 228 149 (65.4) 14 (6.1) 17 (7.5) 27 (11.8) – – 21 (9.2)
Turkmenistan – – – – – – – – – – – – –
Ukraine 7 633 2 948 (38.6) 1 299 (17.0) 1 655 (21.7) 1 371 (18.0) – – 360 (4.7)
Uzbekistan 2 647 1 390 (52.5) 183 (6.9) 512 (19.3) 332 (12.5) – – 230 (8.7)
Subtotal non-EU/EEA 41 207 21 319 (51.7) 5 262 (12.8) 6 413 (15.6) 5 045 (12.2) 0 (0.0) 3 168 (7.7)
Total European Region 42487 21845 (51.4) 5 471 (12.9) 6 592 (15.5) 5 264 (12.4) 86 (0.2) 3 229 (7.6)
Subtotal 18 HPC 42 163 21 677 (51.4) 5 448 (12.9) 6 585 (15.6) 5 231 (12.4) 50 (0.1) 3 172 (7.5)
‘European Region’ comprises the 53 countries of the WHO European Region and Liechtenstein.
RR/MDR TB – rifampicin-resistant and multidrug-resistant tuberculosis.
WHO European Region 18 TB high-priority countries presented in italics.
a
For countries that do not provide information on treatment start, all reported cases were used as proxy.
b
In previous reports defined as ‘defaulted’.
c
In previous reports defined as ‘transferred out and unknown’.
d
In accordance with the UN Security Council Resolution No. 1244 (1999).
70